Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: An open-label pilot study.

Lin Zhang Zhilu Xu Wing Yan Joyce MakKai Ming ChowGrace LuiTimothy C M LiChun Kwok WongPaul Kay Sheung Chan Jessica Yuet Ling ChingYasuhiro FujiwaraFrancis Ka Leung Chan William K K Wu

Published in: Journal of gastroenterology and hepatology (2022)

This proof-of-concept study suggested that the use of a novel gut microbiota-derived synbiotic formula, SIM01, hastened antibody formation against SARS-CoV-2, reduced nasopharyngeal viral load, reduced pro-inflammatory immune markers, and restored gut dysbiosis in hospitalised COVID-19 patients.

Keyphrases

sars cov
respiratory syndrome coronavirus
human milk
early stage
coronavirus disease
preterm infants